DUBLIN, June 15, 2022 /PRNewswire/ — The “Market Overview of Invasive Brain-Computer interface (BCI)” report has been added to ResearchAndMarkets.com’s offering.
Patients with Locked-in Syndrome, who are unable to communicate, represent the target population of Brain-computer Interface research over the past 20 years. In this context, real-time decoding of macroscopic brain states becomes critical.
Patients with Locked-In Syndrome often experience opsoclonus-myoclonus, a condition in which the eyes seemingly randomly and involuntarily move rapidly in the horizontal, vertical, and diagonal directions.
This makes communications extremely difficult, if not impossible, for patients relying on eye communication and typical assistive technology such as the detection of eye movement and voice prosthetics are ineffective, and in the vast majority useless.
Key Topics Covered:
Overview
Number of Motor paralysis due to Spinal Cord Injury
Number of scholarly citations since 2000 on the subject of Locked-in Syndrome
Invasive BCI Companies Funding, million USD
Brain-Computer Interface (BCI)
Risks of using Invasive Brain-Computer Interface (iBCI)
Companies specialized in ECoG microelectrodes with disclosed funding
Companies specialized in Utah microelectrodes with disclosed funding
Takeaways
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/afe2y0
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://healthtechnologynet.com/wp-content/uploads/2022/06/Research_and_Markets_Logo-5.jpg
View original content:https://www.prnewswire.com/news-releases/world-invasive-brain-computer-interface-bci-market-overview-2022-stimulation-recording-utah-electrodes-microecog-ecog-electrodes-301568520.html
SOURCE Research and Markets
Testing nanotechnology to assess for further optimization of manufacturing process at DunmoreOakville, Ontario--(Newsfile Corp. -…
Proceeds Will Support Completion of Pivotal APOLLOE4 Phase 3 Study Evaluating ALZ-801/Valiltramiprosate and Regulatory Filings…
Led by Cortes Capital, LLC, Sorenson Communications, LLC., SMK (Japan), and Hackensack Meridian Health, Series…
WASHINGTON, June 12, 2024 /PRNewswire/ -- Gallup's latest State of the Global Workplace report finds that…
SAN DIEGO, June 12, 2024 /PRNewswire/ -- Alida Biosciences (AlidaBio), an innovator in epigenomic research tools,…
UPPSALA, Sweden, June 12, 2024 /PRNewswire/ -- ScandiNova Group is proud to announce its participation…